Similarly, a separate study presented a cuproptosis-related gene signature (involving TNFRSF18, SLC1A1, among others) to assess patient outcomes and the tumor immune environment, although it lacked clinical sample validation25. The gene discussed is SLC1A1; the disease is neoplasm.